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Abstract
Background—Fibrates are commonly prescribed for hypertriglyceridemia but also lower low-
density lipoprotein cholesterol (LDL-C) and raise high-density lipoprotein cholesterol (HDL-C). 
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Large inter-individual variation in lipid response suggests that some persons may benefit more 
than others and genetic studies could help identify those persons.
Methods—We conducted the first genome-wide association study (GWAS) of lipid response to 
fenofibrate using data from two well characterized clinical trials, the Genetics of Lipid Lowering 
Drugs and Diet Network (GOLDN) Study and the Action to Control Cardiovascular Risk in 
Diabetes (ACCORD) Study. GWAS data from both studies were imputed to the 1000 Genomes 
CEU reference panel (phase 1). Lipid response was modeled as the log ratio of the post-treatment 
lipid level to the pre-treatment level. Linear mixed models (GOLDN, N=813 from 173 families) 
and linear regression models (ACCORD, N=781) adjusted for pre-treatment lipid level, 
demographic variables, clinical covariates, and ancestry were used to evaluate the association of 
genetic markers with lipid response. Among Caucasians, results were combined using inverse-
variance weighted fixed-effects meta-analyses. Top findings from the meta-analyses were 
examined in other ethnic groups from the HyperTG study (N=267 Hispanics) and ACCORD (N= 
83 Hispanics, 138 African Americans).
Results—A known lipid locus harboring the pre-B-cell leukemia homeobox 4 (PBX4) gene on 
chromosome 19 is important for LDL-C response to fenofibrate (smallest p-value = 1.5×10-8). Top 
results replicated with nominal statistical significance in Hispanics from ACCORD (p-value 
<0.05).
Conclusions—Future research should evaluate the usefulness of this locus to refine clinical 
strategies for lipid lowering care.
Keywords
genome-wide association study; GWAS; fenofibrate; triglyceride; cholesterol; lipid; lipoprotein; 
dyslipidemia
Introduction
Hypertriglyceridemia (defined as triglycerides (TG) ≥150 mg/dL) affects 30% of adults over 
the age of 20 years in the United States [1]. Many prospective studies implicate TGs as a 
risk factor for coronary heart disease (CHD) [2]. Despite the evidence, the etiological role of 
TGs in CHD risk has been a topic of considerable debate because of substantial inter-
correlation between lipids, in particular high TGs and low high density lipoprotein 
cholesterol (HDL-C), challenging the premise that the observed TG-CHD risk accurately 
reflects the underlying biological processes [3]. However, recent insights from genetic 
studies convincingly relate lipid metabolism gene variants with TG levels and CHD risk [4, 
5]. These studies add further support for a causal relationship of TG levels to CHD, fueling a 
resurging clinical interest in TG lowering therapies [6, 7].
Fibrates are a class of drugs commonly used to treat hypertriglyceridemia and mixed 
dyslipidemia. They activate nuclear transcription factor peroxisome proliferator-activated 
receptor alpha (PPARα) which is predominantly expressed in tissues that metabolize fatty 
acids, such as the liver, kidney, heart and muscle [8]. Upon activation, PPARα binds with 
retinoid X receptor (RXR) and the resulting dimer anneals to specific PPARα response 
elements in the genome, modulating expression of target lipid metabolism genes. Activated 
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PPARα ultimately upregulates plasma lipoprotein lipase (LPL) activity, raises 
apolipoprotein A-I and apolipoprotein A-II levels, and reduces apolipoprotein CIII, all of 
which enhance the clearance of circulating triglyceride-rich lipoproteins (TRLs). In addition, 
fibrates promote a shift in the density of low density lipoprotein cholesterol (LDL-C) 
particles towards larger, more buoyant particles that are less susceptible to oxidation and 
have increased affinity for the low-density lipoprotein receptor (LDL-R) [9-12]. Among the 
fibrate class, fenofibrate has demonstrated TG and LDL-C lowering effects in the majority 
of subjects, though the magnitude of response is highly variable (24-55% lowering for TGs 
and 6-35% lowering for LDL-C), whereas its effects on HDL-C are typically positive 
(8-38%).
Despite effective lipid lowering, studies have demonstrated both positive [13, 14] and mixed 
[15] results of fibrates in terms of cardiovascular disease (CVD) protection. The beneficial 
effects of fibrates to reduce the incidence of major cardiovascular events were particularly 
pronounced within the Veterans Affairs High-Density Lipoprotein Intervention Trial 
population, especially for patients with type 2 diabetes [16]. In contrast, evaluation of 
fenofibrate in patients with type 2 diabetes in the Fenofibrate Intervention and Event 
Lowering in Diabetes (FIELD) study [15] failed to demonstrate a positive outcome for the 
primary endpoint (CHD death or non-fatal myocardial infarction) and produced mixed 
effects for several of the secondary endpoints. The Action to Control Cardiovascular Risk in 
Diabetes (ACCORD) trial of fenofibrate, which added fenofibrate to baseline simvastatin 
therapy among persons with type 2 diabetes, reported a statistically insignificant 8% 
reduction in cardiovascular events [17]. Reasons for the mixed conclusions are still being 
debated [18]; however, it is apparent that there are large inter-individual variations in TG and 
other lipid fraction responses to fibrate therapy [15]. Response to fenofibrate is heritable 
(39% and 29% for TG and LDL-C response, respectively in the Genetics of Lipid Lowering 
Drugs and Diet Network (GOLDN)) and several candidate gene studies of fenofibrate 
response have been conducted [19-23]. However, there are few data from genome-wide 
scans of lipid response to fenofibrate. In the current study, we conducted genome-wide 
association meta-analyses of ≈7 million variants in a combined sample of 813 Caucasians 
from GOLDN as well as 781 Caucasians from the ACCORD study for lipid response to 
fenofibrate.
Methods
Study Populations
The GOLDN study (N=1,327, clinicaltrials.gov-NCT00083369) was designed to identify 
genes that determine response of lipids to two interventions, one to raise (ingestion of high-
fat meal) and one to lower lipids (fenofibrate treatment). The GOLDN study has been 
previously described in Irvin et al [24]. Briefly, the study ascertained and recruited families 
from the NHLBI Family Heart Study at two centers, Minneapolis, MN and Salt Lake City, 
UT. All of participants were self-reported to be white. Only families with at least two 
siblings were recruited and only participants who did not take lipid-lowering agents 
(pharmaceuticals or nutraceuticals) for at least 4 weeks prior to the initial visit were 
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included. A total of 861 GOLDN participants received open label, once daily 160 mg 
micronized fenofibrate for three weeks and were followed for treatment response.
The ACCORD Trial (N=10,251, clinicaltrials.gov-NCT00000620) was designed to 
determine the effects of intensive treatment of blood glucose vs. standard treatment (with a 
hemoglobin A1c goal of <6% vs. a hemoglobin A1c goal of 7% to 7.9%), and either blood 
pressure (ACCORD Blood Pressure) or plasma lipids (ACCORD Lipid), on atherosclerotic 
CVD outcomes in high risk patients with type 2 diabetes [25]. The ACCORD Lipid trial 
tested the hypothesis that the addition of fenofibrate to background statin treatment in 
patients with type 2 diabetes would further reduce CVD risk compared with statin treatment 
alone by decreasing TG and increasing HDL-C [26]. Patients were eligible to participate in 
the lipid trial if they had the following: LDL-C of 60 to 180 mg per deciliter (1.55 to 4.65 
mmol per liter), HDL-C below 55 mg per deciliter (1.42 mmol per liter) for women and 
African Americans or below 50 mg per deciliter (1.29 mmol per liter) for all other groups, 
and TG levels below 750 mg per deciliter (8.5 mmol per liter) if they were not receiving 
lipid therapy or below 400 mg per deciliter (4.5 mmol per liter) otherwise. All patients 
provided written informed consent. A total of 5,518 men and women with type 2 diabetes 
were enrolled in the ACCORD Lipid trial. All participants received simvastatin (20–40 mg/
day) and were randomly assigned to masked fenofibrate (160 or 54 mg/day, depending on 
renal function) (N=2,765) or placebo (N=2,753) one month after initiation of simvastatin. Of 
the 2765 participants randomized to fenofibrate in the ACCORD lipid trial, genotype 
information was available for 2229 participants. Additional exclusions for the discovery 
analysis included self-reported race other than white (N=730), treatment with fenofibrate at 
baseline (N=77), self-reported fenofibrate compliance criteria not met (described below) 
(N=516), missing lipid levels or other clinical measurements (N=21), and missing 
concomitant medication information (N=104); 781 eligible participants were included in the 
discovery analysis. For a post hoc sensitivity analysis, we further stratified the sample to 
only include patients that were on statins at baseline (∼60%) so that we could test to make 
sure that the genetic associations held in the absence of concomitant statin initiation.
Clinical Data and Lipid Measurements
Clinical lipid measurements (TG, HDL-C, LDL-C, and total cholesterol) pre and post 3 
weeks of fenofibrate treatment in GOLDN have been described [27]. In ACCORD, clinical 
lipid levels were evaluated at a central laboratory at baseline, and on average, 4 months later 
using standardized protocols. Extensive demographic, lifestyle, medical history and clinical 
data collected during the trial by trained staff have been described [25].
Fenofibrate response
In GOLDN, fenofibrate response was defined as post-treatment/pre-treatment ratios of 
plasma concentrations for HDL-C, LDL-C, total cholesterol and TGs. The number of pills 
taken over the three week treatment period was recorded and the average number of pills 
taken per day was derived as the number of pills taken / number of days and used as an 
indicator of compliance. Subjects in the ACCORD lipid trial that were not already treated 
with a statin were started on simvistatin at baseline. Subjects in the fenofibrate arm of the 
ACCORD lipid trial started fenofibrate approximately one month into the trial. Pre-
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treatment lipid levels were recorded at baseline (no more than 60 days prior to the start of 
fenofibrate). Post-treatment lipid levels were acquired after at least 90 days and no more 
than 120 days from the start of fenofibrate treatment. Similarly to GOLDN, fenofibrate 
response was calculated as the ratio of the pre-treatment and post-treatment lipid 
measurements. Only compliant subjects were included (i.e., participants maintained 
compliance on fenofibrate for 90 (+/- 15) consecutive days, and maintained 100% 
compliance ≥ 80% of the recorded visits). Any record of complete non-compliance during 
the 90-day time frame excluded the subject from the selection. If compliance was not 
recorded during the post-treatment visit, the first compliance recorded post-treatment was 
carried backward to fill the missing compliance record.
Genotype Data
In GOLDN, a total of 906,600 single nucleotide polymorphisms (SNPs) were genotyped 
using the Affymetrix Genome-Wide Human 6.0 array and the Birdseed calling algorithm 
[28]. After quality control exclusions, 584,029 genotyped SNPs remained as described by 
Aslibekyan et al. [28]. A two-stage procedure for imputation was used during which data 
was first prephased using MACH and subsequently imputed using MINIMAC with the 
1000G Phase I v3 Shapeit2 Reference (2010-11 data freeze, 2013-09 haplotypes) panel 
(http://www.sph.umich.edu/csg/abecasis/MACH/download/1000G.2013-09.html) with 
singletons and monomorphic sites removed [29]. The imputation yielded, a genotype dataset 
consisting of 27.5 million variants. Markers with R2<0.1 and minor allele frequency 
(MAF)<3% were removed for a final count of 9,003,514 million variants (of which 777,279 
were indels). GOLDN participants were excluded from the analysis if they were missing 
outcome data or genotype data, yielding N= 813 for the single marker analyses. In 
ACCORD, initial genotypes were subjected to quality control to account for duplicate 
concordance, Mendelian segregation (in HapMap trios included on the genotyping plates), 
Hardy-Weinberg Equilibrium, and predicted gender. Cryptic relatedness was identified using 
KING (v1.4), and one member of each pair with a kinship coefficient  was 
removed from the analysis data set [30]. The cleaned dataset consisted 386,212 probes after 
excluding variants with MAF<3%. Probes significantly deviating from HWE (χ2 > 19.51, p-
value < 10−5) in at least two of the three main ethnic subgroups were excluded from the 
imputation process. The remaining untyped genotypes were prephased using SHAPEIT2 
(v2.r778) [31, 32] and imputed using IMPUTE2 [33] to the same 1000G reference panel as 
described for GOLDN for a total of 26,862,499 imputed variants (of which 1,335,851 were 
indels). ACCORD markers with R2<0.1 and MAF<3% were removed for a final count 
7,052,236 million variants (of which 656,466 were indels).
Genome Wide Association Study (GWAS) Analysis
Log-transformations were carried out for each outcome in GOLDN to achieve normality of 
residuals. The SNP associations of interest were assessed using linear mixed models, 
adjusted for the pre-treatment lipid level, sex, age, and center as fixed effects, and a kinship 
coefficient considered as a random effect to adjust for family relatedness using the lmekin 
function in R. The additive assumption was used to model genotypic effects. Population 
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substructure was assessed using principal components (PCs) generated using EIGENSOFT 
3.0 and found to be limited in the GOLDN data. Any of 10 PCs from EIGENSOFT and/or a 
variable called pills per day (to adjust for compliance) were included in the model for a 
particular phenotype if p-value <0.05 after backward selection. The pills per day variable 
was included in the model for both TG and HDL-C response. The third PC was included in 
the model for LDL-C.
Each lipid ratio outcome was log transformed in ACCORD. Covariates including pre-
treatment lipid level (i.e. LDL-C, HDL-C, TG, or total cholesterol), and study arm 
(intensive/standard glycemia treatment) were forced into the models. Additional covariates 
were made available via backwards-selection into the linear model. These covariates 
included: baseline age, gender, BMI, PC1-10, number of years with diabetes, number of 
years with dyslipidemia, smoking, education, glomerular filtration rate, diastolic blood 
pressure, systolic blood pressure, waist size (cm), network, fasting plasma glucose, alcohol 
consumption, and many concomitant medications. Concomitant medications 
(antihypertensive, glycemia and other lipid lowering) were scored according to exposure 
timing in relation to the pre and post fenofibrate lipid measurement (eg. exposed pre-
fenofibrate but stopped medication prior to the post-fenofibrate lipid measure). For a 
complete description of the concomitant medication score as well as scores retained in lipid 
response models see the Supplemental Methods (Supplemental Digital Content 1). PCs 
based on the genotype data were computed using EIGENSTRAT (v4.2), similar to the 
methods described for GOLDN, and were used to control population stratification [34].
Backwards selection by Bayesian information criteria retained the following covariates when 
white subjects were analyzed: TG- statin concomitant medication score and smoking (never 
vs. former vs. current); LDL-C- statin concomitant medication score, duration of diabetes in 
years, duration of dyslipidemia in years, and gender; HDL-C- PC3; total cholesterol- statin 
concomitant medication score, duration of diabetes in years, and duration of dyslipidemia in 
years. Analysis for genotyped SNPs was carried out using PLINK v1.07, and R using lm for 
imputed variants, under an additive genetic model.
Meta-Analysis
Inverse-variance weighted fixed-effects meta-analyses were carried out on the GOLDN and 
ACCORD cohort data using METAL (www.sph.umich.edu/csg/abecasis/metal/). After meta-
analyses, results were filtered to remove SNPs and indels that were missing in either dataset 
for a total of 6,982,258 variants in common between the two studies (of those, 650,503 were 
indels). Statistical heterogeneity was evaluated using Cochrane's χ2 test (Q-test). P-values 
<5×10−8 indicated genome-wide significant results.
Pathway Analysis and other functional annotation analysis
Functional annotation analysis using QIAGEN's Ingenuity® Pathway Analysis tool (IPA® , 
QIAGEN Redwood City, www.qiagen.com/ingenuity) was carried out for each lipid 
response phenotype. We annotated the entire meta-analysis results set for each phenotype to 
a gene where possible (all extra-genic variants were annotated to the nearest gene within 200 
kb; variants >200 kb from a gene were not included in the pathway analysis). The top 200K 
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genes were uploaded into the tool for each lipid. We also used the UCSC genome browser 
(https://genome.ucsc.edu) and the Broad Institute's HaploReg tool v4.1 (http://
www.broadinstitute.org/mammals/haploreg/haploreg.php) to provide further functional 
evidence from ENCODE and other sources in the region of our statistically significant 
findings. Finally, we compared our top results with those published by the Global Lipids 
Genetics Consortium (http://csg.sph.umich.edu//abecasis/public/lipids2013/) [35].
Replication Cohorts
HyperTG recruited 350 Hispanic-American participants from Los Angeles, CA for a 
pharmacogenetic study of the response to fenofibrate (160 mg per day for 8 weeks). Of the 
350 subjects, 267 had available clinical lipid and genotype data (Illumina Metabochip) 
relevant for the replication phase of this study. Similarly to GOLDN, fenofibrate response 
after 4 weeks of treatment was defined as the log ratio of post-treatment/pre-treatment lipid 
level. Linear mixed models were fit to evaluate the associations between variants (under an 
additive genetic model) identified in GOLDN/ACCORD and the outcomes, adjusted for sex, 
age, PCs and pedigree as a random effect.
Only ACCORD participants with self-reported Caucasian race were included in the 
discovery meta-analysis constituting 70% of the ACCORD population. African American 
and Hispanic participants comprised the majority of the remaining subjects and were used as 
an additional replication arm for this study. Using the same criteria described for Caucasians 
a total of 83 Hispanics and 138 African Americans qualified for this analysis. Parallel 
statistical methods were used to evaluate the association of top findings separately in each 
ethnic group. Information regarding covariates selected into the models for Hispanic and 
African American strata are available in the Supplemental Methods (Supplemental Digital 
Content 1).
Results
Baseline characteristics and lipid fenofibrate response for GOLDN and ACCORD are 
presented in Table 1. On average, the ACCORD cohort was older and had fewer female 
participants than GOLDN. By design, the ACCORD cohort was diabetic, while the 
prevalence of diabetes in GOLDN was representative of the US population at large (∼10%) 
[36]. At baseline, ACCORD participants had higher mean TG levels and lower HDL-C 
levels compared to GOLDN. Mean LDL-C and total cholesterol concentrations at baseline 
were higher in GOLDN as compared to ACCORD, likely reflecting the use of statins in 
ACCORD at baseline among a substantial portion of participants (∼60% in ACCORD vs. 
0% in GOLDN). Overall, following 3 weeks of fenofibrate treatment in GOLDN and on 
average 3 months of fenofibrate treatment in ACCORD clinically meaningful lipid changes 
were observed in both intervention studies.
The most significant findings from the discovery meta-analyses of GOLDN and ACCORD 
are listed in Table 2. The Manhattan plots summarizing the results of the genome-wide 
meta-analysis for TG, LDL-C, HDL-C and total cholesterol are shown in Figure 1 panels a-
d, respectively. No SNP or indel was significantly associated with TG, HDL-C or total 
cholesterol. Six unique variants on chromosome 19 in a cluster of genes including ATPase 
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type 13A1 (ATP13A1), pre-B-cell leukemia homeobox 4 (PBX4) and nearby MAU2 
chromatid cohesion factor homolog (MAU2) (∼250 kb upstream of PBX4) were statistically 
significantly associated with LDL-C response to fenofibrate (p-value <5.0*10-8). A regional 
plot for this ∼300kb region is shown in Figure 2. The top finding for TG response 
(rs73199626) was on chromosome 3 in between small ILF3/NF90-associated RNA I 
(SNAR-I) and osteocrin (OSTN) (p-value =8.5*10-7). The top finding for HDL-C 
(rs62041965) was located on chromosome 16 between WW domain containing 
oxidoreductase (WWOX) and v-maf musculoaponeurotic fibrosarcoma oncogene (MAF) 
with p-value =2.6*10-7. We also observed a dense peak for HDL-C response on 
chromosome 15 in or near tumor necrosis factor, alpha-induced protein 8-like 3 
(TNFAIP8L3) with the smallest p-value =4.5*10-7 for rs148486743. Another peak for HDL-
C response was on chromosome 18 near mitochondrial protein NADH dehydrogenase 
(ubiquinone) flavoprotein 2 (NDUFV2) with smallest p-value=7.4*10-7. The top findings for 
total cholesterol were in the G protein-coupled receptor 20 (GPR20) with smallest p-value 
1.1*10-6. For a complete list of results from METAL with p-value<1*10-6 for each lipid 
response please see Supplemental Spreadsheet (Supplemental Digital Content 2). The results 
of the sensitivity analysis among the statin stratified samples from ACCORD Caucasians 
further confirmed the stability of the results. P-values were consistent in their order of 
magnitude and the estimated beta values were identical out to two decimal places (data not 
shown).
One SNP from Table 2 was found on the Metabochip and passed QC in the HyperTG study 
(rs73004962). However, that SNP did not replicate for LDL-C response (p-value>0.05). 
Three results presented in Table 2 approached statistical significance (p-value ∼0.05) in 
African Americans from ACCORD for LDL-C (rs150268548, rs73001065, and 
rs140868651) in the region of MAU2 (see the Supplemental Table, Supplemental Digital 
Content 3). However, for each variant the direction of effect was opposite of that reported for 
Caucasians and the frequency of the effect allele was smaller (∼3.5% vs. ∼8%). Variants in 
PBX4 (rs73004959, rs73004962, rs57504626) were marginally associated with LDL-C 
response in Hispanics from ACCORD (0.02< p-value <0.045) with the same direction of 
effect and similar effect allele frequency (see the Supplemental Table, Supplemental Digital 
Content 3). No SNPs for TG, HDL-C or total cholesterol response from Table 2 were 
replicated even with nominal p-value in other ethnic groups from ACCORD. We also 
searched for additional replication signals located within 500 kb of index variants listed in 
Table 2 for LDL-C response in ACCORD African Americans and Hispanics, filtering out 
variants with imputation quality <0.3, R2 with the index variant in Table 2 <0.5, and 
MAF<1%. Results for ACCORD Hispanics and African Americans are presented in two 
Supplemental Tables (Supplemental Digital Content 4 and 5, respectively). Two SNPs in the 
region of MAU2-PBX4 (rs76244467 and rs74756308) were associated with LDL-C 
response to fenofibrate in Hispanics with p-value <7.0*10-3. One SNP (rs145535422) 
meeting the described criteria was marginally associated with LDL-C response among 
blacks. Those SNPs were rarer than the index variants identified in the meta-analysis 
between ACCORD and GOLDN Caucasians.
Top pathways from the Qiagen's Ingenuity Pathway Analysis tool for each response 
phenotype are provided in Supplemental Digital Content 6. We found the top pathway for 3 
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of the 4 phenotypes is a neurological pathway. The second most significant pathway for 
LDL-C response was PPAR/RXR activation and, importantly, fenofibrate activates this gene 
dimer. This PPAR/RXR pathway was also statistically significant for cholesterol and TG 
response (≤3.76 × 10-3). Supplemental Figure 1 (Supplemental Digital Content 7) 
summarizes annotation results on chromosome 19 in the region of PBX4 output from the 
genome browser. There are several transcription factor binding sites in this gene-rich region 
as evidenced by Transcription factor CHIP-Seq analysis and HMR Conserved Transcription 
Factor Binding Sites. Importantly, a binding site for PPARA can be found in the 3′ region of 
GATAD2A. Two clinically associated SNPS are also (rs137852869 and rs267605377, both 
for cancer types). Examination of this region using the Broad Institute HaploReg tool v4.1 
http://www.broadinstitute.org/mammals/haploreg/haploreg.php) provided further evidence 
of protein binding sites, motif changes, NHGRI GWAS hits and expression QTLs. We have 
provided the results for each of the statistically significant LDL-C variants in Supplemental 
Digital Content 8. Notably, a SNP (rs58434384) in tight LD with our top finding changes a 
motif for PPAR binding with ZNF101.
Discussion
Whether fenofibrate treatment prevents CVD in high risk populations remains a topic of 
debate in the medical community. It is suspected that large inter-individual variation in lipid 
fraction response to fenofibrate has contributed to mixed results for CVD prevention 
reported by clinical studies. Since there is evidence that fenofibrate treatment may offer 
cardioprotective effects for some individuals, research focused on identifying treatment 
responsive persons is a worthy pursuit. To the best of our knowledge, the role of genetic 
factors in fenofibrate response has only been considered at the candidate gene level, making 
this the first genome-wide study of treatment response using data collected on 1600 
participants from two well characterized clinical trials. Overall, our findings support a role 
for a known lipid locus on chromosome 19 in the region of PBX4. Further validation is 
needed to help confirm the importance of this region for fenofibrate response across racial 
groups in order to determine whether markers in the region could be useful for lipid 
lowering treatment strategies in the future.
Several SNPs and indels in or near MAU2, PBX4, and ATP13A1 are listed in Table 2. Three 
of the SNPs replicated with marginal significance in a small group of Hispanics from 
ACCORD. No markers from Table 2 replicated in African Americans from ACCORD. 
Expansion of replication in the region surrounding the index SNPs listed in Table 2 among 
ACCORD Hispanics further suggests this locus may be important for LDL-C fenofibrate 
response (see Supplemental Table, Supplemental Digital Content 4). SNPs in or near PBX4 
and nearby ZNF101 have been associated with fasting lipids and adiposity traits in the 
GWAS literature [37-42]. Three of the statistically significant results for LDL-C from Table 
2 were significantly associated with fasting LDL-C according to the latest published results 
from the Global Lipids Genetics Consortium (rs17217098, rs73004967, rs73001065 
P≤3.6*10-24) [35]. Other published work in GOLDN has suggested variants that are 
associated with fasting lipids in large meta-analyses may be important for lipid response to 
fenofibrate [19]. This region covers ∼ 13 genes and ∼300kb (SUGP1, TM6SF2, MAU2, 
GATAD2A, TSSK6, NDUFA13, YJEFN3, CILP2, PBX4, LPAR2, GMIP, ATP13A1, 
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ZNF101) and finding a causal variant remains challenging (Figure 2). One recent study 
reported a nonsynonymous variant in TM6SF2 influences total cholesterol levels and is 
associated with myocardial infarction. The authors also reported both TM6SF2 
overexpression and knockdown in mice altered serum lipid profiles [43]. There are far fewer 
pharmacogenetic studies of this locus. To our knowledge, only one study examined the 
association of this region with LDL-C response to statin and reported no association among 
895 men with dyslipidemia and 672 normolipidemic controls [44] This locus was also not 
associated with LDL-C response to statin among Caucasians from the placebo arm of 
ACCORD (i.e. participants not treated concomitantly with fenofibrate, data not shown). A 
SNP (rs10401969) in this region in the cartilage intermediate layer protein 2 (CILP2) gene 
(located between MAU2 and PBX4) was marginally linked to LDL-C and total cholesterol 
fenofibrate response in a candidate gene study in GOLDN (with the smallest p-value = 0.03) 
[19]. Given the strength of association of variants in the region with LDL-C response this 
locus is promising, supporting further validation and regional sequencing efforts in search of 
a causal locus. Annotation of this region using freely available bioinformatic tools point to 
PPAR binding sites that may help prioritize follow-up studies.
All of our statistically significant findings were for LDL-C response to fenofibrate. This may 
be due to the heterogenous effect fenofibrate has on TG lowering and HDL raising 
mechanisms such as increased TRL lipolysis, induction of hepatic fatty acid uptake, 
reduction of hepatic TG production, increased production of HDL-C precursors (Apo A-I 
and Apo A-II), and stimulation of reverse cholesterol transport making an effect of 
individual genetic factors difficult to dissect [45]. Nonetheless, we observed at least one 
interesting, marginally significant peak for TG response between SNAR-I and OSTN on 
chromosome 3. OSTN is associated with ostioblastic differentiation, but it is also expressed 
in skeletal muscle and fat and has been linked to glucose and lipid metabolism [46]. We 
found markers near genes linked to inflammation (TNFAIP8L3) and mitochondrial function 
(NDUFV2) marginally associated with HDL-C response to fenofibrate. Pathway analysis did 
not provide substantial further insight into our results. Still many of the top findings could be 
biologically plausibly linked to lipid fenofibrate response and should be considered in 
further studies.
This study has several strengths and limitations, and there are some notable differences 
between the GOLDN and ACCORD populations. Overall, GOLDN represents a healthy 
population and the participants were required to discontinue all lipid lowering medications 
prior to initiating monotherapy with fenofibrate. In contrast, the ACCORD clinical trial 
aimed to evaluate the additional cardioprotective effect of adding fenofibrate to baseline 
statin treatment among persons with type 2 diabetes, and the majority of ACCORD 
participants were on statin prior to starting the trial. We used statistical approaches help 
overcome the potential for confounding by baseline statin use (including a sensitivity 
analysis where ACCORD participants were treatment naïve to fenofibrate but not statin at 
baseline) and other concomitant medication use in ACCORD. The lack of association of the 
top variants on chromosome 19 with LDL-C response to statin in the absence of fenofibrate 
in ACCORD helps support our statistical approach. Despite these notable differences the 
discovery populations were both Caucasian, GWAS data were imputed to the same 1000 
genomes reference panel and clinically significant changes in lipids were observed after 
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initiating fenofibrate treatment. Finally, we observed only marginal replication among 
Hispanics from ACCORD for index SNPs in Table 2 in or near MAU2 and PBX4. Variants 
listed in Table 2 did not replicate in Hispanics from the HyperTG study or African 
Americans from ACCORD. This may be due to small sample size in these other race groups 
considered. Casting a wider net for variants near (<500 kb away) our index variants (with 
R2>0.5 for LD) found additional markers more strongly associated with LDL-C response in 
ACCORD Hispanics and African Americans lending additional support for our findings and 
highlighting the continued need for studying ethnic groups separately to discover fenofibrate 
response variants (see two Supplemental Tables, Supplemental Digital Content 3 and 4).
Clinical data demonstrating the cardiovascular benefit of lipid lowering with the drug 
fenofibrate have shown mixed results. To date the drug has largely fallen out of clinical 
favor. However, wide variability in lipid response has been demonstrated, suggesting the 
drug may provide some benefits in specific persons or subgroups. Genetic factors predicting 
favorable lipid altering response to fenofibrate represent prime candidates for understanding 
these individual differences and thus provide an opportunity for possible pre-emptive 
genotyping to guide clinical decisions related to individualizing drug selection. Herein, we 
took a genome-wide approach representing data on ∼ 1600 people. Overall, our results 
demonstrate a known lipid locus is associated with LDL-C response to fenofibrate. Future 
studies should consider whether this well known locus on chromosome 19 is useful to 
determine the best lipid lowering treatment regimen.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Manhattan Plot of Meta-Analysis P-values derived from the discovery in GOLDN and 
ACCORD Caucasians for triglyercide (a), LDL-C (b), HDL-C (c) and total cholesterol (D) 
response to fenofibrate
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Figure 2. Regional plot of GOLDN/ACCORD top SNVs on chromosome 19
Irvin et al. Page 16
Pharmacogenet Genomics. Author manuscript; available in PMC 2017 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Irvin et al. Page 17
Table 1
Baseline characteristics and lipid response to fenofibrate in GOLDN and ACCORD 
studies
GOLDN ACCORD
Variable (mean ± SD or %) N=820 N=781
Age 49±16 63.6±6.3
Sex % Female 50 28
Current Smoker % 8 13
BMI, Kg/m2 28±6 33±5
Diabetes (%) 7.5% 100%
Triglycerides, mg/dL
Baseline 139.9±98.97 196.82±104.57
After fenofibrate treatment 92.91±57.99 144.77±83.68
Low density lipoprotein, mg/dL
Baseline 118.53±32.57 99.40±29.53
After fenofibrate treatment 104.92±31.34 90.08±24.42
High density lipoprotein, mg/dL
Baseline 45.02±13.62 37.23±7.41
After fenofibrate treatment 49.16±13.33 40.34±9.63
Total Cholesterol, mg/dL
Baseline 191.71±39.83 174.97±36.24
After fenofibrate treatment 167.16±34.71 158.83±30.74
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